TriSalus Life Sciences Unveils TriNav FLX Infusion System with Enhanced Trackability and Precision for Solid Tumor Treatment

Reuters

06-04

TriSalus Life Sciences Unveils TriNav FLX Infusion System with Enhanced Trackability and Precision for Solid Tumor Treatment

TriSalus Life Sciences® Inc. has announced the launch of the TriNav® FLX Infusion System, marking a significant advancement in their TriNav portfolio. This new system retains the trusted Pressure-Enabled Drug DeliveryTM benefits but introduces a design enhancement with twice the length of more flexible material at the distal end, improving navigation through challenging vascular pathways. In benchtop models, the TriNav FLX demonstrated a 28% reduction in force during navigation compared to the standard design. The system is also eligible for reimbursement under HCPCS codes C8004 and C9797, allowing for both planning and treatment procedures. This innovation aims to enhance the capabilities of Interventional Radiologists in treating patients with complex peripheral vessel anatomy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trisalus Life Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250604718518) on June 04, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2540214063"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540214063\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2540214063?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-04 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540214063","market":"nz","top_or_hot":-1,"title":"TriSalus Life Sciences Unveils TriNav FLX Infusion System with Enhanced Trackability and Precision for Solid Tumor Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TriSalus Life Sciences Unveils TriNav FLX Infusion System with Enhanced Trackability and Precision for Solid Tumor Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TriSalus Life Sciences® Inc. has announced the launch of the TriNav® FLX Infusion System, marking a significant advancement in their TriNav portfolio. This new system retains the trusted Pressure-Enabled Drug DeliveryTM benefits but introduces a design enhancement with twice the length of more flexible material at the distal end, improving navigation through challenging vascular pathways. In benchtop models, the TriNav FLX demonstrated a 28% reduction in force during navigation compared to the standard design. The system is also eligible for reimbursement under HCPCS codes C8004 and C9797, allowing for both planning and treatment procedures. This innovation aims to enhance the capabilities of Interventional Radiologists in treating patients with complex peripheral vessel anatomy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trisalus Life Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250604718518) on June 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TriSalus Life Sciences Unveils TriNav FLX Infusion System with Enhanced Trackability and Precision for Solid Tumor Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTriSalus Life Sciences Unveils TriNav FLX Infusion System with Enhanced Trackability and Precision for Solid Tumor Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-04 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TriSalus Life Sciences Unveils TriNav FLX Infusion System with Enhanced Trackability and Precision for Solid Tumor Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TriSalus Life Sciences® Inc. has announced the launch of the TriNav® FLX Infusion System, marking a significant advancement in their TriNav portfolio. This new system retains the trusted Pressure-Enabled Drug DeliveryTM benefits but introduces a design enhancement with twice the length of more flexible material at the distal end, improving navigation through challenging vascular pathways. In benchtop models, the TriNav FLX demonstrated a 28% reduction in force during navigation compared to the standard design. The system is also eligible for reimbursement under HCPCS codes C8004 and C9797, allowing for both planning and treatment procedures. This innovation aims to enhance the capabilities of Interventional Radiologists in treating patients with complex peripheral vessel anatomy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trisalus Life Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250604718518) on June 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL1TCJPm:1","article_id":"2540214063","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540214063","pubTimestamp":1749038491,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"TriSalus Life Sciences Inc. has announced the launch of the TriNav FLX Infusion System, marking a significant advancement in their TriNav portfolio. This new system retains the trusted Pressure-Enabled Drug DeliveryTM benefits but introduces a design enhancement with twice the length of more flexible material at the distal end, improving navigation through challenging vascular pathways. In benchtop models, the TriNav FLX demonstrated a 28% reduction in force during navigation compared to the standard design. The system is also eligible for reimbursement under HCPCS codes C8004 and C9797, allowing for both planning and treatment procedures. This innovation aims to enhance the capabilities of Interventional Radiologists in treating patients with complex peripheral vessel anatomy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informatio","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"TriSalus Life Sciences推出TriNav FLX输注系统，可增强实体瘤治疗的可追踪性和精确度","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLSI":0.9},"content_text":"TriSalus Life Sciences Unveils TriNav FLX Infusion System with Enhanced Trackability and Precision for Solid Tumor Treatment\n    \n\n        TriSalus Life Sciences® Inc. has announced the launch of the TriNav® FLX Infusion System, marking a significant advancement in their TriNav portfolio. This new system retains the trusted Pressure-Enabled Drug DeliveryTM benefits but introduces a design enhancement with twice the length of more flexible material at the distal end, improving navigation through challenging vascular pathways. In benchtop models, the TriNav FLX demonstrated a 28% reduction in force during navigation compared to the standard design. The system is also eligible for reimbursement under HCPCS codes C8004 and C9797, allowing for both planning and treatment procedures. This innovation aims to enhance the capabilities of Interventional Radiologists in treating patients with complex peripheral vessel anatomy.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trisalus Life Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250604718518) on June 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}